Priyanka Chopra Jonas and Crocs to Donate 50,000 Pairs of Classic Clogs to UNICEF
Crocs, Inc. (NASDAQ: CROX), in partnership with UNICEF Goodwill Ambassador Priyanka Chopra Jonas, today announced that 50,000 pairs of Crocs Classic clogs will be donated over the next year to underserved school children in Belize through UNICEF. This charitable contribution supports the actor’s joint mission to help children around the world and provide them with more opportunities to achieve an education.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005213/en/
In partnership with UNICEF Goodwill Ambassador and Crocs Global Brand Ambassador Priyanka Chopra Jonas, Crocs recently donated 25,000 pairs of Classic Clogs to underserved school children in Belize through UNICEF. This is the first of two donations to be made to this region through this partnership. A total of 50,000 pairs will ultimately be donated over the next year. (Photo: Business Wire)
Recently, Crocs announced award-winning actor, activist, and entrepreneur Priyanka Chopra Jonas would serve as a global brand ambassador for its 2020 “Come As You Are” marketing campaign. A special element of the partnership is this collaboration to jointly support UNICEF.
“At Crocs, we believe being comfortable in your own shoes is a first step to accessing quality education,” said Heidi Cooley, Vice President of Global Marketing, Crocs. “With this donation, we hope to deliver shoes to more than half of the student population attending primary and secondary school classes in Belize, while reducing the financial burden for their families.”
“As a global ambassador for UNICEF, I’m dedicated to connecting organizations that together can have a large and positive impact on children around the world,” said Priyanka Chopra Jonas. “Working with Crocs to distribute more than 50,000 pairs of their Classic Clogs will have a tremendous impact on school-age children in Belize, reducing barriers to education, and easing social and peer-related stressors that come with not having basic everyday resources that many take for granted.”
Barriers to education in Belize include poverty, disability, late entry, and inadequate preparation for primary school, among other factors. In November, members of UNICEF USA and Crocs visited Belize, where they distributed an initial 25,000 pairs of Crocs – the first of two parts of this donation – to students. A video documenting that journey and showing first-hand the positive impact of the contribution can be found linked here.
“UNICEF USA is grateful for Crocs’ generous shoe donation to help remove one of the barriers that can hinder school attendance in Belize, especially during early childhood education,” said Gabriella Morris, Senior Vice President of Strategic Partnerships, UNICEF USA. “Education is essential for children to live to their fullest potential, and together, we can help give each child the opportunity for quality education.”
About Crocs, Inc.
Crocs, Inc. (NASDAQ: CROX) is a world leader in innovative casual footwear for women, men, and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram, and Twitter.
About UNICEF
The United Nations Children's Fund (UNICEF) works in more than 190 countries and territories to put children first. UNICEF has helped save more children’s lives than any other humanitarian organization, by providing health care and immunizations, clean water and sanitation, nutrition, education, emergency relief, and more. UNICEF USA supports UNICEF's work through fundraising, advocacy, and education in the United States. Together, we are working toward the day when no children die from preventable causes and every child has a safe and healthy childhood. For more information, visit www.unicefusa.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005213/en/
Contact information
Media Contacts:
Crocs
Melissa Layton
mlayton@crocs.com
UNICEF
Ann Reinking Whitener
areinking@unicefusa.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom